AIZ vs JAZZ
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
AIZ · Assurant$307.00 ▲ 0.04%
JAZZ · Jazz Pharmaceuticals$234.76 ▲ 3.27%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- AIZ +37.8%
- JAZZ +76.3%
Head to head
| Metric | AIZ | JAZZ |
|---|---|---|
| Price | $307.00 | $234.76 |
| Change today | ▲ 0.04% | ▲ 3.27% |
| Market cap | $15.06B | $15.07B |
| Return, 3 months | +7.2% | -8.5% |
| Return, year to date | +28.8% | +38.1% |
| Return, 1 year | +38.9% | +79.0% |
| P/E (TTM) | 14.5 | 69.5 |
| P/B | 2.5 | 3.6 |
| P/E percentile vs own 5y | 52nd | 89th |
| Dividend yield | 1.15% | – |
| Revenue growth (YoY, latest qtr) | +9.4% | +15.5% |
| Net profit growth (YoY) | +26.9% | +126.8% |
| Gross margin | – | 88.4% |
| Operating margin | – | 22.1% |
| Net margin | 7.8% | 20.4% |
| Return on equity | 18.2% | 22.1% |
| Analyst target vs. price | +5.9% | +30.5% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 73 | 60 |
| 30-day volatility | 21.7% | 37.8% |
| Max drawdown, 1 year | -12.9% | -21.6% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- JAZZ is the largest of the group by market value.
- JAZZ has returned the most over the past year.
- AIZ carries the lowest trailing P/E.
- JAZZ is growing revenue fastest.
- JAZZ keeps the most profit per dollar of sales.
- AIZ has been the calmest stock over the last 30 days.